Premium
Histopathologic correlation of high‐risk MelaFind TM lesions: a 3‐year experience from a high‐risk pigmented lesion clinic
Author(s) -
Shrivastava Vikas,
Bailin Phillip,
Elliott Jennifer,
Bacnik Elizabeth,
Gastman Brian,
Bergfeld Wilma,
Billings Steven D.,
Piliang Melissa,
Fernandez Anthony,
Kovalyshyn Ivanka,
Ko Jennifer S.
Publication year - 2019
Publication title -
international journal of dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.677
H-Index - 93
eISSN - 1365-4632
pISSN - 0011-9059
DOI - 10.1111/ijd.14336
Subject(s) - medicine , dysplastic nevus , dysplasia , biopsy , melanoma , atypia , nevus , lesion , dermatology , pathology , medical diagnosis , cancer research
Background A significant number of pigmented lesions are biopsied to rule out melanoma, but most will be benign. MelaFind TM is a highly sensitive, noninvasive computer‐assisted system to aid in clinical diagnosis of melanoma. Methods A total of 140 high‐risk patients were followed by one expert dermatologist. Biopsies were blindly and independently evaluated by two dermatopathologists and given histologic severity scores ( HSS , 0–12) based on the histologic features of melanoma/dysplastic nevi and compared to pathologic diagnoses and MelaFind TM scores. Results MelaFind TM reduced the biopsy number of clinically ambiguous lesions (923 scanned to 253 biopsied, 73% reduction). Biopsied cases were usually benign (135/253, 53.4%, HSS = 2.8–3.2). Dysplastic nevi with varying degrees of atypia were observed next most commonly (80/253, 31.6%, HSS = 4.7–5.2 for mild dysplasia and 7–7.6 for moderate to severe dysplasia). Melanomas comprised 11/253 (4.3%) of biopsies ( HSS = 9.3–10.7). Twenty‐four cases were given miscellaneous diagnoses not within the dysplastic nevus–melanoma spectrum (9.5%, HSS = 1.3). Dermal fibrosis was the most commonly identified worrisome histologic feature (177/253, 70%), closely followed by other known atypical features. Nonthreatening histologic features in benign lesions with high MelaFind TM disorganization scores were common. The HSS differed significantly depending on pathologic diagnosis severity, while the MelaFind TM score did not (benign = 2.2; mildly atypical = 4.8; moderately to severely atypical = 2.3; in‐situ or invasive melanoma = 3.1). Conclusions MelaFind TM unequivocally reduced the number of biopsies, but banal lesions had histologic attributes resulting in high‐risk MelaFind TM scores, and MelaFind TM does not correlate with degree of cytologic atypia. Knowledge of these limitations should increase bidirectional confidence when making clinicopathologic correlations in high‐risk patients.